These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 23381796)

  • 1. A decision-analysis tool for benefit-risk assessment of nonprescription drugs.
    Brass EP; Lofstedt R; Renn O
    J Clin Pharmacol; 2013 May; 53(5):475-82. PubMed ID: 23381796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the decision-making process for nonprescription drugs: a framework for benefit-risk assessment.
    Brass EP; Lofstedt R; Renn O
    Clin Pharmacol Ther; 2011 Dec; 90(6):791-803. PubMed ID: 22048228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis.
    Mussen F; Salek S; Walker S
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S2-S15. PubMed ID: 17546573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A decision support tool to prioritize risk management options for contaminated sites.
    Sorvari J; Seppälä J
    Sci Total Environ; 2010 Mar; 408(8):1786-99. PubMed ID: 20138649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and test of a decision support tool for hospital health technology assessment.
    Sampietro-Colom L; Morilla-Bachs I; Gutierrez-Moreno S; Gallo P
    Int J Technol Assess Health Care; 2012 Oct; 28(4):460-5. PubMed ID: 23062518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visually defining and querying consistent multi-granular clinical temporal abstractions.
    Combi C; Oliboni B
    Artif Intell Med; 2012 Feb; 54(2):75-101. PubMed ID: 22177662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new perspective on nonprescription statins: an opportunity for patient education and involvement.
    Fuster V
    Am J Cardiol; 2007 Sep; 100(5):907-10. PubMed ID: 17719344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of PKPD relationships into benefit-risk analysis.
    Bellanti F; van Wijk RC; Danhof M; Della Pasqua O
    Br J Clin Pharmacol; 2015 Nov; 80(5):979-91. PubMed ID: 25940398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive approach to benefit-risk assessment in drug development.
    Sarac SB; Rasmussen CH; Rasmussen MA; Hallgreen CE; Søeborg T; Colding-Jørgensen M; Christensen PK; Thirstrup S; Mosekilde E
    Basic Clin Pharmacol Toxicol; 2012 Jul; 111(1):65-72. PubMed ID: 22356197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The identification of benefit in medical intervention: an overview and suggestions for process.
    Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
    Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State of the art in benefit-risk analysis: food and nutrition.
    Tijhuis MJ; de Jong N; Pohjola MV; Gunnlaugsdóttir H; Hendriksen M; Hoekstra J; Holm F; Kalogeras N; Leino O; van Leeuwen FX; Luteijn JM; Magnússon SH; Odekerken G; Rompelberg C; Tuomisto JT; Ueland Ø; White BC; Verhagen H
    Food Chem Toxicol; 2012 Jan; 50(1):5-25. PubMed ID: 21679741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit-risk assessment: the use of clinical utility index.
    Ouellet D
    Expert Opin Drug Saf; 2010 Mar; 9(2):289-300. PubMed ID: 20175698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. u-SHARE: web-based decision support/risk communication tool for healthcare consumers with unruptured intracranial aneurysms.
    Aoki N; Sakai M; Nakayama T; Fukuhara S; Ohta S; Kikuchi N; Oishi M; Kiuchi T; Nozaki K; Hashimoto N
    Stud Health Technol Inform; 2007; 129(Pt 2):1012-6. PubMed ID: 17911868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A new decision support tool in the campaign against maternal mortality: the Dystocia Risk Score].
    Ndiaye P; Diallo I; Wone I; Fall C
    Sante; 2001; 11(2):133-8. PubMed ID: 11440893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.